Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Incidence And Severity Of Drug Interactions Before And After Switching Antiretroviral Therapy To Bictegravir/Emtricitabine/Tenofovir Alafenamide In Treatment-Experienced Patients., Jason J. Schafer, Pharmd, Mph, Bcps, Aahivp, Neha S Pandit, Agnes Cha, Emily Huesgen, Melissa Badowski, Elizabeth M Sherman, Jennifer Cocohoba, Ayako Shimada, Scott W Keith
Incidence And Severity Of Drug Interactions Before And After Switching Antiretroviral Therapy To Bictegravir/Emtricitabine/Tenofovir Alafenamide In Treatment-Experienced Patients., Jason J. Schafer, Pharmd, Mph, Bcps, Aahivp, Neha S Pandit, Agnes Cha, Emily Huesgen, Melissa Badowski, Elizabeth M Sherman, Jennifer Cocohoba, Ayako Shimada, Scott W Keith
College of Pharmacy Faculty Papers
Background: Switching antiretroviral therapy (ART) in people with HIV (PWH) can influence their risk for drug-drug interactions (DDIs). The purpose of this study was to assess changes in the incidence and severity of DDIs among PWH who switched their ART to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Methods: This was a multicenter retrospective cohort study of PWH on ART and at least 1 concomitant medication (CM) who switched to BIC/FTC/TAF between 3/2018 and 6/2019. Using the University of Liverpool's HIV Drug Interaction Database, 2 DDI analyses were performed for each patient. The first assessed patients' preswitch ART regimens with their CM list. The …